Important Resource
CJ Bioscience announced on July 25 that it has confirmed a total of 15 microbiome drug pipelines, setting the record for the highest number globally among microbiome drug development companies.
In March, CJ Bioscience commenced pipeline analysis work after acquiring promising drug candidates from 4D Pharma, a microbiome drug development company based in the U.K. and Ireland.
CJ Bioscience has completed the classification of pipelines that can synergize with existing pipelines, focusing on drug candidates with a high likelihood of successful development. The company also plans to accelerate drug development by building a sophisticated and proprietary bacterial strain library and database using the European intestinal microbiome-related data acquired along with the pipelines.
Currently, CJ Bioscience has a total of 15 pipelines, including 4 developed in-house and 11 acquired from 4D Pharma. The in-house development pipelines target solid tumors, Inflammatory Bowel Disease (IBD), and asthma, while the acquired pipelines target diseases including solid tumors, IBD, Irritable Bowel Syndrome (IBS), asthma, and Parkinson’s disease.
Through this pipeline acquisition, CJ Bioscience has achieved its goal of securing 10 pipelines by 2025, which was announced at its launch in January 2022, more than two years ahead of schedule. This gives the company a competitive edge in the industry, both quantitatively and qualitatively.
An official from CJ Bioscience stated, “Global pharmaceutical giants are showing interest in several pipelines, including CJRB-101. The number of clinical pipelines is a measure of a drug development company’s competitiveness, and securing these pipelines will lay the foundation for our continued growth.”